Therapeutic antibodies against amyloid aggregates
This technology is an antibody-based platform that binds transmembrane protein 106B (TMEM106B) amyloid aggregates to diagnose and treat neurodegenerative diseases.
Unmet Need: Therapeutic targets for pathogenic protein aggregates in neurodegenerative disease
Protein aggregation is a hallmark of many neurogenerative diseases, yet current diagnostic and therapeutic strategies rely largely on nonspecific biomarkers, post-mortem pathology, or treatments that do not directly address aggregation-driven disease progression. As a result, there is a critical lack of tools capable of selectively recognizing pathogenic protein aggregates across these diseases, limiting accurate diagnosis and therapeutic effectiveness.
The Technology: Antibody platform for selective targeting of protein aggregates
This technology is an IgG and IgM-based antibody platform that selectively binds to the C-terminal fragment of transmembrane protein 106B (TMEM106B) aggregates. TMEM106B forms amyloid fibrils in multiple neurodegenerative diseases, enabling these antibodies to selectively recognize aggregation states associated with neurodegenerative pathology.
Applications:
- Biomarker for pathogenic protein aggregation
- Therapeutics targeting neurodegenerative disease-associated aggregates
- Research tool for studying protein aggregation mechanisms in disease
Advantages:
- Selective recognition of pathogenic protein aggregates
- Platform to discriminate aggregated from non-aggregated protein states
- Applicable across multiple neurodegenerative diseases
- Diagnostic and research application for protein aggregation
Lead Inventor:
Anthony William Paul Fitzpatrick, Ph.D.
Patent Information:
Patent Pending (WO/2025/117530)
Related Publications:
Tech Ventures Reference:
IR CU23354
Licensing Contact: Kristin Neuman